Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Dominik Paul Modest(Berliner Hochschule für Technik), Anke Reinacher‐Schick(Ruhr University Bochum), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arndt Stahler(Ludwig-Maximilians-Universität München), Dirk Arnold(Asklepios Klinik Altona), Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Rainer Porschen(Klinikum Bremen-Mitte), Andrea Tannapfel(Leipzig University), Andreas Jung(Ludwig-Maximilians-Universität München), Ullrich Graeven(Kliniken Maria Hilf), S. Hegewisch-Becker(HOPE Clinic), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Ingrid Ricard(Zimmer Biomet (Netherlands)), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Clemens Gießen-Jung
Cited by 344
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k